首页> 中文期刊> 《中国医院用药评价与分析》 >2013-2015年北京安贞医院胰岛素类抗糖尿病药应用分析

2013-2015年北京安贞医院胰岛素类抗糖尿病药应用分析

         

摘要

To investigate the application characteristics, safety and development tendency of insulin antidiabetics in clinic, so as to provide reference for the rational application of insulin antidiabetics.METHODS: Retrospective analysis method was adopted, statistical analysis was conducted on the data of insulin antidiabetics in terms of consumption amount, consumption sum, defined daily dose system ( DDDs ) and defined daily cost ( DDC ) , etc.. RESULTS:The consumption sum of insulin antidiabetics in our hospital during 2013-2015 were respectively 1 511.48 million yuan, 1 641.69 million yuan and 1 740.18 million yuan; the DDDs were respectively 1 320 900.0, 1 306 850.0,1 306 507.5,compared with 2013,the DDDs decreased by 1.06%in 2014;and compared with 2014, the DDDs decreased by 0.02% in 2015.The clinical application of isophane protamine biosynthetic human insulin (premixed 30 R), insulin aspart, insulin aspart 30, protamine zinc recombinant human insulin were frequent, the DDDs of which dominated the top 4 places.And insulin antidiabetics with great synchronisation were respectively isophane protamine biosynthetic human insulin ( premixed 30 R ) , protamine zinc recombinant human insulin and insulin aspart.CONCLUSIONS:The clinical application of insulin antidiabetics in our hospital was basically rational, which should be attached more importance.The clinic should comprehensively consider the individualized medication, so as to ensure the rational application of insulin antidiabetics.%目的:了解胰岛素类抗糖尿病药的临床使用特点、安全性及发展趋势,为临床合理应用胰岛素类抗糖尿病药提供参考。方法:采取回顾性分析方法,对2013—2015年首都医科大学附属北京安贞医院(以下简称“我院”)胰岛素类抗糖尿病药的销售数量、销售金额、用药频度( defined daily dose system,DDDs)、限定日费用等进行统计分析。结果:2013—2015年我院胰岛素类抗糖尿病药的销售金额分别为1511.48、1641.69、1740.18万元,2014年较2013年增长了8.61%,2015年较2014年增长了6.00%;2013—2015年我院胰岛素类抗糖尿病药的DDDs分别为1320900.0、1306850.0、1306507.5,2014年较2013年降低了1.06%,2015年较2014年降低了0.02%。精蛋白生物合成人胰岛素(预混30R)、门冬胰岛素、门冬胰岛素30、精蛋白锌重组人胰岛素的临床应用较多,其DDDs排序居前4位;同步性良好的胰岛素类抗糖尿病药有精蛋白生物合成人胰岛素(预混30R)、精蛋白锌重组人胰岛素和门冬胰岛素。结论:我院胰岛素类抗糖尿病药的临床应用基本合理,其安全性也受到重视。临床应综合考虑、个体化用药,确保胰岛素类抗糖尿病药的合理应用。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号